Marek Biestek insider trades: Kalobios Pharmaceuticals (KBIO) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Marek reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 16, 2015 | KBIO | ↑ Buy | 10,000 | $29.32 | $293K | Direct | Dec 18, 2015 (2d) |
| Nov 18, 2015 | KBIO | ↑ Buy | 40,000 | $2.04 | $82K | Direct | Nov 19, 2015 (1d) |
| Nov 17, 2015 | KBIO | ↑ Buy | 200,000 | $1.68 | $335K | Direct | Nov 19, 2015 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Marek Biestek's insider trades
Marek Biestek is a director at Kalobios Pharmaceuticals (KBIO). Since Nov 17, 2015, Marek has reported 3 open-market purchases worth $710K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.